Please login to the form below

Not currently logged in
Email:
Password:

Sir Christopher Gent 'stepping down' as GSK chair

He will leave the pharma firm in the next two or three years, according to a UK press report

Sir Christopher Gent, GSKSir Christopher Gent will leave his position as chair of the UK's largest pharma firm GlaxoSmithKline (GSK) within the next two to three years, according to the Daily Telegraph.

The UK newspaper reported Sir Christopher, who has served in the position for more than seven years, is currently preparing to step down and headhunters are now seeking a potential successor.

During his time at GSK, Sir Christopher has seen the company retain its position as one of the largest pharma companies in the world, expand into emerging markets, such as China, and handle mammoth settlements following legal investigations into the marketing of several products, the most high profile being its diabetes drug Avandia.

He also appointed Sir Andrew Witty as CEO in 2008 following the departure of Jean-Pierre Garnier.

Prior to joining GSK in 2004, Sir Christopher spent nearly 20 years at Vodafone, serving as managing director from 1985 to 1997 and then as CEO until 2003. He is credited with turning the British mobile phone company into one the world's largest.

Other positions Sir Christopher has held include non-executive directorship at Lehman Brothers from 2003 to 2008 and he is currently a non-executive director at Ferrari.

Responding to a query from PMLiVE, a GSK spokesperson acknowledged the Daily Telegraph report but declined to comment on the matter.

30th October 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics